Biontech Se ADR (BNTX)

$90.93 +0.57 (0.63%)
Market Cap 22.85B
Revenue (ttm) 3.25B
Net Income (ttm) -1.29B
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -39.59%
Debt to Equity Ratio 0.02
Volume 958,400
Avg Vol 969,196
Day's Range N/A - N/A
Shares Out 252.88M
Stochastic %K 37%
Beta 1.36
Analysts Strong Sell
Price Target $133.11

Company Profile

BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell lung cancer and advanced/metastatic triple-negative breast cancer, and Trastuzumab pamirtecan for metastatic breast cancer and epirubicin a...

Industry: Biotechnology
Sector: Healthcare
Phone: 49 6131 9084
Fax: 49 6131 9084
Address:
An der Goldgrube 12, Mainz, Germany
AIIAAIIA_88
AIIAAIIA_88 May. 22 at 12:07 PM
$BNTX Judging from the OI of put options (11,000 at $80 strike), there are many skeptics of BNTX being able to succeed with its cancer pipeline. Oh, ho… the bears and short sellers will have a horrid year… lol. I am just saying..
0 · Reply
htw7448
htw7448 May. 22 at 10:10 AM
$BNTX heavy premarket volume
0 · Reply
htw7448
htw7448 May. 22 at 9:37 AM
$BNTX image Keytruda losing his SOC to Pumitamig. 25 Billion$ per year! If this happen and data already hinting it … impressive growth ahead! The actual Market cap is a joke nothing of the news is priced in!
0 · Reply
eightytwentie
eightytwentie May. 22 at 12:24 AM
$BNTX https://www.asco.org/abstracts-presentations/261380
0 · Reply
eightytwentie
eightytwentie May. 21 at 11:58 PM
$BNTX poontang getting that ORR 72.7%
1 · Reply
eightytwentie
eightytwentie May. 21 at 11:57 PM
$BNTX poontangmiggg let’s goooo
0 · Reply
SoYeonPicks
SoYeonPicks May. 21 at 11:16 PM
$BNTX great Phase 2 data from ROSETTA Lung-02!!
0 · Reply
OPEN_LIFE
OPEN_LIFE May. 21 at 9:25 PM
$BNTX let’s go
0 · Reply
eightytwentie
eightytwentie May. 21 at 9:15 PM
$BNTX yes https://news.bms.com/news/corporate-financial/2026/Bristol-Myers-Squibb-to-Unveil-New-Data-at-ASCO-2026-Demonstrating-Strength-and-Breadth-of-Scientific-Innovation-Across-Oncology-Portfolio-and-Next-Generation-Pipeline/default.aspx
0 · Reply
Estimize
Estimize May. 21 at 11:03 AM
Wall St is expecting -2.44 EPS for $BNTX Q2 [Reporting 08/04 BMO] http://www.estimize.com/intro/bntx?chart=historical&metric_name=eps&utm_c
0 · Reply
Latest News on BNTX
BioNTech to Showcase Progress Across Late-Stage Oncology Pipeline at the 2026 ASCO Annual Meeting

May 22, 2026, 5:00 AM EDT - 4 hours ago

BioNTech to Showcase Progress Across Late-Stage Oncology Pipeline at the 2026 ASCO Annual Meeting

Bernstein starts BioNTech at Market Perform, sees high registration risk

2026-05-21T21:20:11.000Z - 16 hours ago

Bernstein starts BioNTech at Market Perform, sees high registration risk

BioNTech initiated with a Market Perform at Bernstein

2026-05-21T20:27:55.000Z - 16 hours ago

BioNTech initiated with a Market Perform at Bernstein

BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2026

May 15, 2026, 4:15 PM EDT - 6 days ago

BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2026

BioNTech Maps Oncology Push, $1B Buyback and Manufacturing Cuts at AGM

May 15, 2026, 12:10 PM EDT - 6 days ago

BioNTech Maps Oncology Push, $1B Buyback and Manufacturing Cuts at AGM

BioNTech SE Transcript: AGM 2026

May 15, 2026, 8:00 AM EDT - 7 days ago

BioNTech SE Transcript: AGM 2026

Berenberg cuts BioNTech target, says shares ‘deeply’ undervalued

2026-05-12T08:30:54.000Z - 10 days ago

Berenberg cuts BioNTech target, says shares ‘deeply’ undervalued

BioNTech announces new $1B ADS repurchase program

2026-05-07T14:04:55.000Z - 14 days ago

BioNTech announces new $1B ADS repurchase program

BioNTech Announces New ADS Repurchase Program

May 7, 2026, 6:45 AM EDT - 15 days ago

BioNTech Announces New ADS Repurchase Program

BioNTech price target lowered to $158 from $171 at Canaccord

2026-05-07T07:26:08.000Z - 15 days ago

BioNTech price target lowered to $158 from $171 at Canaccord

Germany says vaccine supply secure despite BioNTech production loss

May 6, 2026, 7:44 AM EDT - 16 days ago

Germany says vaccine supply secure despite BioNTech production loss

BioNTech to cut up to 1,860 jobs, close multiple global sites, Reuters reports

2026-05-05T15:41:20.000Z - 16 days ago

BioNTech to cut up to 1,860 jobs, close multiple global sites, Reuters reports

PFE

BioNTech SE Earnings Call Transcript: Q1 2026

May 5, 2026, 8:00 AM EDT - 17 days ago

BioNTech SE Earnings Call Transcript: Q1 2026

BioNTech SE Earnings release: Q1 2026

May 5, 2026, 8:00 AM EDT - 17 days ago

BioNTech SE Earnings release: Q1 2026

BioNTech SE Slides: Q1 2026

May 5, 2026, 8:00 AM EDT - 17 days ago

BioNTech SE Slides: Q1 2026

BioNTech to Close Sites, Cut Quarter of Workforce in Savings Push

May 5, 2026, 7:26 AM EDT - 17 days ago

BioNTech to Close Sites, Cut Quarter of Workforce in Savings Push

BioNTech reaffirms FY26 revenue view EUR2.000B- EUR2.300B

2026-05-05T11:14:49.000Z - 17 days ago

BioNTech reaffirms FY26 revenue view EUR2.000B- EUR2.300B

BioNTech to close sites in Germany, Singapore affecting 1,860 staff

May 5, 2026, 6:47 AM EDT - 17 days ago

BioNTech to close sites in Germany, Singapore affecting 1,860 staff

BioNTech Announces First Quarter 2026 Financial Results and Corporate Update

May 5, 2026, 6:45 AM EDT - 17 days ago

BioNTech Announces First Quarter 2026 Financial Results and Corporate Update

Two experimental drugs showed striking early results against pancreatic cancer

Apr 21, 2026, 5:35 PM EDT - 4 weeks ago

Two experimental drugs showed striking early results against pancreatic cancer

RVMD

BioNTech to Report First Quarter 2026 Financial Results and Corporate Update on May 5, 2026

Apr 21, 2026, 6:45 AM EDT - 4 weeks ago

BioNTech to Report First Quarter 2026 Financial Results and Corporate Update on May 5, 2026

BioNTech price target raised to $130 from $128 at BofA

2026-04-13T12:01:10.000Z - 5 weeks ago

BioNTech price target raised to $130 from $128 at BofA

BioNTech announce Phase 2 cohort of BNT323 met primary efficacy endpoint

2026-04-12T16:20:47.000Z - 5 weeks ago

BioNTech announce Phase 2 cohort of BNT323 met primary efficacy endpoint

BioNTech and DualityBio's Antibody-Drug Conjugate Trastuzumab Pamirtecan Demonstrated Clinically Meaningful Efficacy in Patients with HER2-Expressing, Recurrent Endometrial Cancer

Apr 11, 2026, 7:00 AM EDT - 5 weeks ago

BioNTech and DualityBio's Antibody-Drug Conjugate Trastuzumab Pamirtecan Demonstrated Clinically Meaningful Efficacy in Patients with HER2-Expressing, Recurrent Endometrial Cancer

BioNTech price target raised to $126 from $125 at Morgan Stanley

2026-04-10T13:03:03.000Z - 6 weeks ago

BioNTech price target raised to $126 from $125 at Morgan Stanley

Exclusive: Pfizer, BioNTech halt US COVID vaccine study after recruitment struggles

Apr 1, 2026, 11:39 AM EDT - 7 weeks ago

Exclusive: Pfizer, BioNTech halt US COVID vaccine study after recruitment struggles

PFE

BioNTech price target lowered to $130 from $140 at H.C. Wainwright

2026-03-31T10:16:25.000Z - 7 weeks ago

BioNTech price target lowered to $130 from $140 at H.C. Wainwright

BioNTech Clinical Data at ELCC 2026 Highlight Potential of Differentiated Late-Stage Portfolio in Lung Cancer

Mar 24, 2026, 6:45 AM EDT - 2 months ago

BioNTech Clinical Data at ELCC 2026 Highlight Potential of Differentiated Late-Stage Portfolio in Lung Cancer

BioNTech price target lowered to $94 from $116 at TD Cowen

2026-03-11T12:10:41.000Z - 2 months ago

BioNTech price target lowered to $94 from $116 at TD Cowen

BioNTech price target lowered to $125 from $134 at Morgan Stanley

2026-03-11T11:56:02.000Z - 2 months ago

BioNTech price target lowered to $125 from $134 at Morgan Stanley

BioNTech SE Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Mar 10, 2026, 2:48 PM EDT - 2 months ago

BioNTech SE Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

One simple reason why BioNTech stock is a raging buy on today's crash

Mar 10, 2026, 1:29 PM EDT - 2 months ago

One simple reason why BioNTech stock is a raging buy on today's crash

BioNTech SE Earnings Call Transcript: Q4 2025

Mar 10, 2026, 8:00 AM EDT - 2 months ago

BioNTech SE Earnings Call Transcript: Q4 2025

BioNTech SE Annual report: Q4 2025

Mar 10, 2026, 8:00 AM EDT - 2 months ago

BioNTech SE Annual report: Q4 2025

BioNTech SE Earnings release: Q4 2025

Mar 10, 2026, 8:00 AM EDT - 2 months ago

BioNTech SE Earnings release: Q4 2025

BioNTech SE Slides: Q4 2025

Mar 10, 2026, 8:00 AM EDT - 2 months ago

BioNTech SE Slides: Q4 2025

Scientists behind COVID-19 vaccine will depart BioNTech

Mar 10, 2026, 7:40 AM EDT - 2 months ago

Scientists behind COVID-19 vaccine will depart BioNTech

BioNTech Plunges as Drugmaker Swings to a Loss. More Than Earnings Are Weighing on the Stock.

Mar 10, 2026, 7:18 AM EDT - 2 months ago

BioNTech Plunges as Drugmaker Swings to a Loss. More Than Earnings Are Weighing on the Stock.

BioNTech Cofounders to Leave to Form New Company

Mar 10, 2026, 6:50 AM EDT - 2 months ago

BioNTech Cofounders to Leave to Form New Company

BioNTech's founding couple Sahin, Tuereci to leave to set up new venture

Mar 10, 2026, 6:49 AM EDT - 2 months ago

BioNTech's founding couple Sahin, Tuereci to leave to set up new venture

BioNTech Announces Fourth Quarter and Full Year 2025 Financial Results and Corporate Update

Mar 10, 2026, 6:45 AM EDT - 2 months ago

BioNTech Announces Fourth Quarter and Full Year 2025 Financial Results and Corporate Update

BioNTech and Co-Founders Announce Plan to Pursue Next-Generation mRNA Innovations in Co-Founders-Led New Company as BioNTech Advances Toward Becoming a Multi-Product Company by 2030

Mar 10, 2026, 6:33 AM EDT - 2 months ago

BioNTech and Co-Founders Announce Plan to Pursue Next-Generation mRNA Innovations in Co-Founders-Led New Company as BioNTech Advances Toward Becoming a Multi-Product Company by 2030

BioNTech to Report Fourth Quarter and Full Year 2025 Financial Results and Corporate Update on March 10, 2026

Feb 24, 2026, 6:45 AM EST - 3 months ago

BioNTech to Report Fourth Quarter and Full Year 2025 Financial Results and Corporate Update on March 10, 2026

BioNTech sues Moderna for patent infringement over COVID-19 shots

Feb 19, 2026, 1:25 PM EST - 3 months ago

BioNTech sues Moderna for patent infringement over COVID-19 shots

MRNA

BioNTech Announces Appointment of Kylie Jimenez to Management Board as Chief People Officer

Jan 28, 2026, 8:00 AM EST - 4 months ago

BioNTech Announces Appointment of Kylie Jimenez to Management Board as Chief People Officer

BioNTech SE Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 13, 2026, 5:15 PM EST - 4 months ago

BioNTech SE Transcript: 44th Annual J.P. Morgan Healthcare Conference

BioNTech SE Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 13, 2026, 5:15 PM EST - 4 months ago

BioNTech SE Slides: 44th Annual J.P. Morgan Healthcare Conference

BioNTech Provides Strategic Business Update and Outlines 2026 Areas of Focus at 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 6:45 AM EST - 4 months ago

BioNTech Provides Strategic Business Update and Outlines 2026 Areas of Focus at 44th Annual J.P. Morgan Healthcare Conference

University of Pennsylvania, BioNTech, and OUP Launch $50 Million Life Sciences Fund

Jan 9, 2026, 10:00 AM EST - 4 months ago

University of Pennsylvania, BioNTech, and OUP Launch $50 Million Life Sciences Fund

BioNTech Closes Acquisition of CureVac N.V. Including Subsequent Offering Period to Strengthen its Unique Position in the mRNA Field

Dec 18, 2025, 4:45 AM EST - 5 months ago

BioNTech Closes Acquisition of CureVac N.V. Including Subsequent Offering Period to Strengthen its Unique Position in the mRNA Field

BioNTech and Bristol Myers Squibb Present First Global Phase 2 Data for PD-L1xVEGF-A Bispecific Antibody Pumitamig Showing Encouraging Efficacy in Advanced Triple-Negative Breast Cancer

Dec 9, 2025, 7:00 AM EST - 5 months ago

BioNTech and Bristol Myers Squibb Present First Global Phase 2 Data for PD-L1xVEGF-A Bispecific Antibody Pumitamig Showing Encouraging Efficacy in Advanced Triple-Negative Breast Cancer

BMY

BioNTech and OncoC4 Announce Clinically Meaningful Overall Survival Benefit for Selective Treg Modulator Gotistobart in Patients with Previously Treated Squamous Non-Small Cell Lung Cancer

Dec 6, 2025, 3:30 PM EST - 5 months ago

BioNTech and OncoC4 Announce Clinically Meaningful Overall Survival Benefit for Selective Treg Modulator Gotistobart in Patients with Previously Treated Squamous Non-Small Cell Lung Cancer

BioNTech Achieves Minimum Condition in CureVac Exchange Offer

Dec 3, 2025, 9:01 AM EST - 6 months ago

BioNTech Achieves Minimum Condition in CureVac Exchange Offer

CVAC

FDA Plans to Tighten Vaccine Approvals Weigh on These Stocks

Dec 1, 2025, 3:50 PM EST - 6 months ago

FDA Plans to Tighten Vaccine Approvals Weigh on These Stocks

MRNA NVAX PFE

Vaccine stocks take a hit as FDA official points to link between COVID-19 vaccines and rare heart condition in young men

Dec 1, 2025, 12:35 PM EST - 6 months ago

Vaccine stocks take a hit as FDA official points to link between COVID-19 vaccines and rare heart condition in young men

MRNA NVAX PFE

BioNTech Shares Progress on Exchange Offer for CureVac Shares and Highlights December 3, 2025, at 9:00 a.m. Eastern Time Expiration

Nov 26, 2025, 7:30 AM EST - 6 months ago

BioNTech Shares Progress on Exchange Offer for CureVac Shares and Highlights December 3, 2025, at 9:00 a.m. Eastern Time Expiration

Pfizer sheds BioNTech stake years after blockbuster COVID vaccine tie-up

Nov 13, 2025, 5:20 PM EST - 6 months ago

Pfizer sheds BioNTech stake years after blockbuster COVID vaccine tie-up

PFE

BioNTech says collaboration with Pfizer remains unchanged

Nov 13, 2025, 8:17 AM EST - 6 months ago

BioNTech says collaboration with Pfizer remains unchanged

PFE

BioNTech SE Transcript: R&D Day

Nov 11, 2025, 9:00 AM EST - 6 months ago

BioNTech SE Transcript: R&D Day

BioNTech SE Slides: R&D Day

Nov 11, 2025, 9:00 AM EST - 6 months ago

BioNTech SE Slides: R&D Day

BioNTech SE Earnings Call Transcript: Q3 2025

Nov 3, 2025, 8:00 AM EST - 7 months ago

BioNTech SE Earnings Call Transcript: Q3 2025

BioNTech SE Earnings release: Q3 2025

Nov 3, 2025, 8:00 AM EST - 7 months ago

BioNTech SE Earnings release: Q3 2025

BioNTech SE Slides: Q3 2025

Nov 3, 2025, 8:00 AM EST - 7 months ago

BioNTech SE Slides: Q3 2025

BioNTech lifts 2025 revenue guidance on BMS partnership payment

Nov 3, 2025, 6:47 AM EST - 7 months ago

BioNTech lifts 2025 revenue guidance on BMS partnership payment

BioNTech Announces Third Quarter 2025 Financial Results and Corporate Update

Nov 3, 2025, 6:45 AM EST - 7 months ago

BioNTech Announces Third Quarter 2025 Financial Results and Corporate Update

BioNTech to Host Innovation Series R&D Day on November 11, 2025

Oct 28, 2025, 7:45 AM EDT - 7 months ago

BioNTech to Host Innovation Series R&D Day on November 11, 2025

BioNTech to Report Third Quarter 2025 Financial Results and Corporate Update on November 3, 2025

Oct 27, 2025, 7:45 AM EDT - 7 months ago

BioNTech to Report Third Quarter 2025 Financial Results and Corporate Update on November 3, 2025

BioNTech Commences Public Exchange Offer for All Outstanding Shares of CureVac N.V.

Oct 22, 2025, 6:45 AM EDT - 7 months ago

BioNTech Commences Public Exchange Offer for All Outstanding Shares of CureVac N.V.

BioNTech SE Transcript: AI Day 2025

Oct 1, 2025, 9:00 AM EDT - 8 months ago

BioNTech SE Transcript: AI Day 2025

BioNTech SE Slides: FY 2025

Oct 1, 2025, 9:00 AM EDT - 8 months ago

BioNTech SE Slides: FY 2025

BioNTech to Host Second AI Day as an Edition of Its Innovation Series on October 1, 2025

Sep 23, 2025, 6:45 AM EDT - 8 months ago

BioNTech to Host Second AI Day as an Edition of Its Innovation Series on October 1, 2025

Mizuho's Jared Holz: There's not much value left in vaccine stocks

Sep 19, 2025, 11:40 AM EDT - 8 months ago

Mizuho's Jared Holz: There's not much value left in vaccine stocks

MRNA NVAX PFE

COVID vaccine makers' shares fall as Trump officials to link shots to child deaths, report says

Sep 12, 2025, 1:37 PM EDT - 8 months ago

COVID vaccine makers' shares fall as Trump officials to link shots to child deaths, report says

JNJ KVUE MRNA PFE

BioNTech, Bristol Myers' immunotherapy shows encouraging tumour shrinkage in Phase II trial

Sep 8, 2025, 11:05 AM EDT - 9 months ago

BioNTech, Bristol Myers' immunotherapy shows encouraging tumour shrinkage in Phase II trial

BMY

First Disclosure of Global Interim Phase 2 Data for BioNTech and Bristol Myers Squibb PD-L1xVEGF-A Bispecific Antibody Pumitamig (BNT327/BMS986545) in Patients with Extensive-Stage Small Cell Lung Cancer Shows Encouraging Antitumor Activity

Sep 8, 2025, 11:00 AM EDT - 9 months ago

First Disclosure of Global Interim Phase 2 Data for BioNTech and Bristol Myers Squibb PD-L1xVEGF-A Bispecific Antibody Pumitamig (BNT327/BMS986545) in Patients with Extensive-Stage Small Cell Lung Cancer Shows Encouraging Antitumor Activity

Pfizer, partner BioNTech say updated COVID shot shows better immune response

Sep 8, 2025, 7:02 AM EDT - 9 months ago

Pfizer, partner BioNTech say updated COVID shot shows better immune response

PFE

Pfizer and BioNTech Announce Topline Data Demonstrating Robust Immune Response With Their LP.8.1-Adapted COVID-19 Vaccine 2025-2026 Formula

Sep 8, 2025, 6:45 AM EDT - 9 months ago

Pfizer and BioNTech Announce Topline Data Demonstrating Robust Immune Response With Their LP.8.1-Adapted COVID-19 Vaccine 2025-2026 Formula

PFE

BioNTech, Duality score initial trial win with breast cancer precision drug

Sep 5, 2025, 5:13 AM EDT - 9 months ago

BioNTech, Duality score initial trial win with breast cancer precision drug

Pfizer and BioNTech's COMIRNATY® Receives U.S. FDA Approval for Adults 65 and Older and Individuals Ages 5 through 64 at Increased Risk for Severe COVID-19

Aug 27, 2025, 12:50 PM EDT - 9 months ago

Pfizer and BioNTech's COMIRNATY® Receives U.S. FDA Approval for Adults 65 and Older and Individuals Ages 5 through 64 at Increased Risk for Severe COVID-19

PFE

CureVac settles patent dispute litigation with Pfizer and BioNTech

Aug 7, 2025, 9:00 PM EDT - 10 months ago

CureVac settles patent dispute litigation with Pfizer and BioNTech

CVAC PFE

AIIAAIIA_88
AIIAAIIA_88 May. 22 at 12:07 PM
$BNTX Judging from the OI of put options (11,000 at $80 strike), there are many skeptics of BNTX being able to succeed with its cancer pipeline. Oh, ho… the bears and short sellers will have a horrid year… lol. I am just saying..
0 · Reply
htw7448
htw7448 May. 22 at 10:10 AM
$BNTX heavy premarket volume
0 · Reply
htw7448
htw7448 May. 22 at 9:37 AM
$BNTX image Keytruda losing his SOC to Pumitamig. 25 Billion$ per year! If this happen and data already hinting it … impressive growth ahead! The actual Market cap is a joke nothing of the news is priced in!
0 · Reply
eightytwentie
eightytwentie May. 22 at 12:24 AM
$BNTX https://www.asco.org/abstracts-presentations/261380
0 · Reply
eightytwentie
eightytwentie May. 21 at 11:58 PM
$BNTX poontang getting that ORR 72.7%
1 · Reply
eightytwentie
eightytwentie May. 21 at 11:57 PM
$BNTX poontangmiggg let’s goooo
0 · Reply
SoYeonPicks
SoYeonPicks May. 21 at 11:16 PM
$BNTX great Phase 2 data from ROSETTA Lung-02!!
0 · Reply
OPEN_LIFE
OPEN_LIFE May. 21 at 9:25 PM
$BNTX let’s go
0 · Reply
eightytwentie
eightytwentie May. 21 at 9:15 PM
$BNTX yes https://news.bms.com/news/corporate-financial/2026/Bristol-Myers-Squibb-to-Unveil-New-Data-at-ASCO-2026-Demonstrating-Strength-and-Breadth-of-Scientific-Innovation-Across-Oncology-Portfolio-and-Next-Generation-Pipeline/default.aspx
0 · Reply
Estimize
Estimize May. 21 at 11:03 AM
Wall St is expecting -2.44 EPS for $BNTX Q2 [Reporting 08/04 BMO] http://www.estimize.com/intro/bntx?chart=historical&metric_name=eps&utm_c
0 · Reply
OnlyFibs
OnlyFibs May. 21 at 2:37 AM
$BNTX — $600K in $95C expiring 6/18 BioNTech. $3.83 avg. 4 weeks. mRNA cancer vaccine pipeline. Someone expects a specific near-term catalyst before June 18. 🐂 Pipeline catalyst hits and this prints. $600K says they expect something specific. 🐻 4 weeks no catalyst = premium gone. ⚠️ Near-term BioNTech call flow right as the mRNA space heats up. #hovdid 📊 Lean: BULL — binary. Catalyst shows or it doesn't.
0 · Reply
AIIAAIIA_88
AIIAAIIA_88 May. 21 at 2:25 AM
$BNTX With so bullish catalysts for cancer clinical pipeline milestone readouts, this stock could be $180 - $270 by the end of this year. Yes, double or triple current price. JMO
0 · Reply
SoYeonPicks
SoYeonPicks May. 20 at 10:46 PM
$BNTX big things coming
0 · Reply
WallStJesus
WallStJesus May. 20 at 2:13 PM
$BNTX BULL BET ..
0 · Reply
taxplanr
taxplanr May. 20 at 1:31 PM
Cancer free in 9 months with Ivermectin and Fenbendazole $BNTX $MRNA $MRK $BMY https://makisw.substack.com/p/ivermectin-and-fenbendazole-testimonial-f61?utm_source=post-email-title&publication_id=1385328&post_id=197939877&utm_campaign=email-post-title&isFreemail=true&r=18m8lm&triedRedirect=true&utm_medium=email
0 · Reply
htw7448
htw7448 May. 19 at 3:35 PM
$BNTX wake up call for the keytruda killer
0 · Reply
htw7448
htw7448 May. 19 at 2:19 PM
$BNTX big keytruda fuck incoming :)
0 · Reply
OPEN_LIFE
OPEN_LIFE May. 19 at 12:08 PM
$BMY $BNTX $IBRX $SPY let’s go BioNTech
0 · Reply
OPEN_LIFE
OPEN_LIFE May. 19 at 11:18 AM
$BNTX anyone expecting we will rally hard on Thursday after 5?
2 · Reply
OPEN_LIFE
OPEN_LIFE May. 19 at 11:09 AM
$BNTX good find
0 · Reply
htw7448
htw7448 May. 19 at 9:25 AM
$BNTX a lot of new information on 30 th of may. https://meetings.asco.org/meetings/2026-asco-annual-meeting/335/program-guide/scheduled-sessions/search?q=biontech
0 · Reply
OPEN_LIFE
OPEN_LIFE May. 19 at 2:25 AM
$BMY $BNTX $IBRX $SPY let’s go
0 · Reply